Skip to content

Search Results

No Matching Results

    Recently Viewed


      HomeMedia CenterPress releases PharmaceuticalsJohnson & Johnson Ranked as Pharma Industry’s Most Productive Innovator for the Second Consecutive Year

      Johnson & Johnson Ranked as Pharma Industry’s Most Productive Innovator for the Second Consecutive Year

      Share Article
      share to

      When discovery and commercialization come together, true innovation is born. For the second year in a row, IDEA Pharma has given Johnson & Johnson the top spot, as the most productive pharmaceutical innovator, in its fourth annual Productive Innovation Index (PII). The PII measures and ranks companies based upon their ability to not only discover but also commercialize new medicines. It celebrates one of the things we hold most dear at Janssen — collaboration.

      “This award is a great win for our entire organization,” says Paul Stoffels, M.D., Worldwide Chairman and Johnson & Johnson Chief Scientific Officer. “It recognizes and validates what we have always known — successful innovation requires a collaborative approach both in the lab and in the field.”

      The PII assesses companies based on a range of factors including speed to market, attrition rate in phase III, reimbursement rates, regulatory approvals and analyst rankings. It also takes into account other factors such as R&D strategy changes, company restructuring and commercialization strategies.

      “Our approach to science and innovation is the envy of many in the industry,” notes Joaquin Duato, Worldwide Chairman, “but what also sets us apart is the strategic way we’re able to commercialize our innovations — delivering powerful medicines to the patients who need them, quickly and efficiently.”

      According to IDEA Pharma, Johnson & Johnson maintained its first place ranking due to successes in CNS, oncology, immunology and metabolism, including two notable launches in 2013 — IMBRUVICA™ (ibrutinib), which achieved breakthrough designation (BTD) for mantle cell lymphoma, and the first-in-class INVOKANA® (canaglifozin) for type 2 diabetes. Other factors that kept us in the top spot include higher than average investment in R&D, six NME/BLA approvals in the last three years, and a significant amount of revenue growth from recent launches.

      “Some of the companies that talk constantly of ‘innovation’ are surprisingly underwhelming at bringing it to market, but on the flip side there are others — quietly — doing it exceptionally well and we want to applaud them,” said Mike Rea, CEO of IDEA Pharma. “Their successes are the ones that fuel us all, and that bring valuable new medicines to market.”

      You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.